Published in Mol Ther on May 31, 2011
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | NCT03072134
Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med (2013) 1.42
A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm (2011) 1.27
The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry (2012) 1.24
A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst (2013) 1.21
Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int (2014) 1.18
Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther (2012) 1.08
How stem cells speak with host immune cells in inflammatory brain diseases. Glia (2013) 1.08
Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev (2013) 1.07
Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells (2013) 1.03
Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro Oncol (2011) 0.96
Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice. Front Oncol (2013) 0.95
Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma? Oncotarget (2013) 0.93
Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem Cells Transl Med (2013) 0.92
The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Stem Cells Transl Med (2013) 0.91
Neural stem cell-mediated intratumoral delivery of gold nanorods improves photothermal therapy. ACS Nano (2014) 0.91
Strategies in gene therapy for glioblastoma. Cancers (Basel) (2013) 0.87
Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy. Front Microbiol (2014) 0.87
Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities. Front Cell Neurosci (2015) 0.86
N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy. Mol Ther (2013) 0.85
Gene therapy for malignant glioma. Mol Cell Ther (2014) 0.83
Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy. Oncotarget (2015) 0.83
Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol Ther (2014) 0.82
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No? J Cancer (2015) 0.81
Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases. Stem Cells (2015) 0.81
Subventricular zone localized irradiation affects the generation of proliferating neural precursor cells and the migration of neuroblasts. Stem Cells (2012) 0.81
Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making? Future Virol (2013) 0.79
Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro Oncol (2012) 0.79
Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction. Cancer Gene Ther (2014) 0.79
Neural stem cell-mediated delivery of oncolytic adenovirus. Curr Protoc Hum Genet (2015) 0.79
Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy. Ther Deliv (2015) 0.78
Monitoring adenoviral based gene delivery in rat glioma by molecular imaging. World J Clin Oncol (2013) 0.78
Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions. Viruses (2015) 0.78
MMP14 as a novel downstream target of VEGFR2 in migratory glioma-tropic neural stem cells. Stem Cell Res (2015) 0.77
Controlled Payload Release by Magnetic Field Triggered Neural Stem Cell Destruction for Malignant Glioma Treatment. PLoS One (2016) 0.76
Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters. J Transl Med (2016) 0.76
Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy (2017) 0.75
Enhanced oncolytic virotherapy through oxidative stress inhibition. Mol Ther (2013) 0.75
Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytic Virother (2013) 0.75
Use of genetically engineered stem cells for glioma therapy. Oncol Lett (2015) 0.75
Three-dimensional assessment of bystander effects of mesenchymal stem cells carrying a cytosine deaminase gene on glioma cells. Am J Cancer Res (2015) 0.75
Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma. Stem Cell Reports (2016) 0.75
Immune System, Friend or Foe of Oncolytic Virotherapy? Front Oncol (2017) 0.75
Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A (2000) 5.49
Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature (2003) 5.31
Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature (2005) 3.53
Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med (2000) 3.51
The innate immune response to adenovirus vectors. Hum Gene Ther (2004) 2.35
Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus (2006) 2.25
Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther (2008) 2.10
Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis. Proc Natl Acad Sci U S A (2010) 2.00
Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest (2004) 1.85
Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther (2009) 1.72
The changing face of neural stem cell therapy in neurologic diseases. Arch Neurol (2008) 1.58
Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther (2007) 1.48
Subacute encephalomyelitis of AIDS and its relation to HTLV-III infection. Neurology (1987) 1.39
Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res (2007) 1.38
Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther (2008) 1.36
Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Curr Opin Mol Ther (2006) 1.19
Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res (1999) 1.11
Neural stem cell migration toward gliomas in vitro. Neuro Oncol (2005) 1.10
Astrocytes: form, functions, and roles in disease. Vet Pathol (1994) 1.05
Role of monocyte chemoattractant protein-1 (MCP-1/CCL2) in migration of neural progenitor cells toward glial tumors. J Neurosci Res (2009) 1.04
Vascular endothelial growth factor-stimulated cerebral microvascular endothelial cells mediate the recruitment of neural stem cells to the neurovascular niche. Brain Res (2009) 1.03
Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma. Hum Gene Ther (2007) 0.98
Advances in oncolytic virus therapy for glioma. Recent Pat CNS Drug Discov (2009) 0.94
Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther (2009) 0.91
Neural progenitor cell-mediated delivery of osteoprotegerin limits disease progression in a preclinical model of neuroblastoma bone metastasis. J Pediatr Surg (2009) 0.91
Virotherapy against malignant glioma stem cells. Cancer Lett (2009) 0.91
Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy. J Med Virol (2008) 0.91
Brain-IL-1 beta triggers astrogliosis through induction of IL-6: inhibition by propranolol and IL-10. Med Sci Monit (2004) 0.90
Crossing the boundaries: stem cells and gene therapy. Discov Med (2010) 0.83
Downregulation of CXCR4 gene expression in primary human endothelial cells following infection with E1(-)E4(+) adenovirus gene transfer vectors. Mol Ther (2000) 0.83
Astrocyte activation by Sindbis virus: expression of GFAP, cytokines, and adhesion molecules. Glia (1997) 0.81
Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci (2001) 0.78
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med (2008) 5.87
Simultaneous phase and size control of upconversion nanocrystals through lanthanide doping. Nature (2010) 3.53
Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer (2005) 2.89
Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. Int J Biochem Cell Biol (2007) 2.78
Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction. Nat Mater (2009) 2.02
Tuning upconversion through energy migration in core-shell nanoparticles. Nat Mater (2011) 2.00
Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res (2004) 1.93
An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol (2006) 1.92
Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. Stroke (2011) 1.91
Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol (2011) 1.89
Tomato transcription factors pti4, pti5, and pti6 activate defense responses when expressed in Arabidopsis. Plant Cell (2002) 1.86
Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells (2008) 1.74
Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg (2006) 1.73
Neural stem cell tropism to glioma: critical role of tumor hypoxia. Mol Cancer Res (2008) 1.67
Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther (2003) 1.65
Chemokines in tumor progression and metastasis. Oncotarget (2013) 1.64
IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res (2012) 1.55
Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One (2007) 1.54
Regulation of renalase expression by D5 dopamine receptors in rat renal proximal tubule cells. Am J Physiol Renal Physiol (2014) 1.50
Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol (2007) 1.49
Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther (2007) 1.48
Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res (2004) 1.45
Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res (2006) 1.44
Melanoma B16-F1 cells coated with fusion protein of mouse calreticulin and virus G-protein coupled receptor induced the antitumor immune response in Balb/C mice. Cancer Biol Ther (2011) 1.43
Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia (2005) 1.41
Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res (2007) 1.38
Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS One (2009) 1.36
Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis. Immunity (2010) 1.35
CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol (2007) 1.35
Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells (2008) 1.30
Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci (2009) 1.30
Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res (2008) 1.30
Functional single-cell hybridoma screening using droplet-based microfluidics. Proc Natl Acad Sci U S A (2012) 1.29
The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg (2010) 1.28
Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med (2010) 1.28
A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm (2011) 1.27
Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma. Expert Rev Anticancer Ther (2007) 1.27
Mechanisms of immune evasion by gliomas. Adv Exp Med Biol (2012) 1.26
Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia (2006) 1.26
The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry (2012) 1.24
PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res (2010) 1.23
A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst (2013) 1.21
The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg (2006) 1.21
A high-performance nanobio photocatalyst for targeted brain cancer therapy. Nano Lett (2009) 1.19
The role of regulatory T cells in malignant glioma. Anticancer Res (2008) 1.18
WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med (2013) 1.17
Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med (2007) 1.15
The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Curr Opin Mol Ther (2010) 1.15
Human neural stem cell tropism to metastatic breast cancer. Stem Cells (2012) 1.13
Generating rate equations for complex enzyme systems by a computer-assisted systematic method. BMC Bioinformatics (2009) 1.12
Predictors of intra-community variation in air quality. J Expo Sci Environ Epidemiol (2012) 1.12
The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget (2011) 1.10
Repression of tyrosine hydroxylase is responsible for the sex-linked chocolate mutation of the silkworm, Bombyx mori. Proc Natl Acad Sci U S A (2010) 1.10
The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One (2010) 1.09
Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling. Stem Cells (2008) 1.09
Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS One (2010) 1.08
Synovial joint morphogenesis requires the chondrogenic action of Sox5 and Sox6 in growth plate and articular cartilage. Dev Biol (2010) 1.08
Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells. J Neurooncol (2006) 1.08
Transmembrane pores formed by human antimicrobial peptide LL-37. Biophys J (2011) 1.08
High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene (2012) 1.08
Sub-10 nm Fe3O4@Cu(2-x)S core-shell nanoparticles for dual-modal imaging and photothermal therapy. J Am Chem Soc (2013) 1.08
MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Targets (2013) 1.07
CD46 represents a target for adenoviral gene therapy of malignant glioma. Hum Gene Ther (2006) 1.07
Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use. Stem Cells Transl Med (2013) 1.07
Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp Hematol (2003) 1.06
Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther (2007) 1.05
Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One (2009) 1.05
Neural stem cell biology may be well suited for improving brain tumor therapies. Cancer J (2003) 1.05
Multi-objective dynamic population shuffled frog-leaping biclustering of microarray data. BMC Genomics (2012) 1.05
The role of late/slow replication of the FRA16D in common fragile site induction. Genes Chromosomes Cancer (2004) 1.05
Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther (2010) 1.04
Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs (2012) 1.03
Vascular endothelial growth factor-stimulated cerebral microvascular endothelial cells mediate the recruitment of neural stem cells to the neurovascular niche. Brain Res (2009) 1.03
Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther (2010) 1.02